Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of upadacitinib in moderate to severe hidradenitis suppurativa after TNF inhibitor failure
MOH_2023-06-26_012769Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in hidradenitis suppurativa (HS) (9 arms), sponsored by AbbVie Inc. Started Jun 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2023-06-26_012769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-26_012769.